TSRL, Inc.
TSRL, Inc. is a privately owned preclinical accelerator based in Ann Arbor, Michigan, dedicated to advancing promising therapeutics for treating severe and multi-drug resistant infections. They provide infrastructure, scientific expertise, and wet-lab data to help drug-therapy concepts reach business formation or licensing-readiness, focusing on anti-infective compounds and innovative drug delivery technologies.
Industries
Nr. of Employees
small (1-50)
TSRL, Inc.
540 Avis Dr., Suite A, Ann Arbor, MI 48108
Products
Topical ocular antiviral prodrug (nucleoside phosphonate prodrug)
A nucleoside phosphonate prodrug designed to deliver an active antiviral warhead to ocular tissues to treat adenovirus and other dsDNA viral infections with improved potency and safety relative to parent compounds.
Oral methionyl‑tRNA synthetase inhibitor antibiotic candidate
A novel small‑molecule antibiotic series that inhibits bacterial methionyl‑tRNA synthetase with potential oral administration for treatment of Gram‑positive infections.
Microneedle / microarray patch for antiviral and transdermal delivery
Microarray patch prototypes for transdermal delivery of antiviral agents and other payloads to enable non‑invasive delivery routes and potential stockpiling use cases.
Dendrimer‑based heparin reversal therapeutic (preclinical candidate)
A dendrimer‑based platform candidate intended to neutralize heparin activity with the goal of a wider therapeutic window and improved safety relative to existing reversal agents.
Synthetic HDL (sHDL) formulation candidate for infection complications
An sHDL lead candidate designed to treat infection‑related complications such as sepsis, progressed through preclinical development toward GLP toxicology.
Topical ocular antiviral prodrug (nucleoside phosphonate prodrug)
A nucleoside phosphonate prodrug designed to deliver an active antiviral warhead to ocular tissues to treat adenovirus and other dsDNA viral infections with improved potency and safety relative to parent compounds.
Oral methionyl‑tRNA synthetase inhibitor antibiotic candidate
A novel small‑molecule antibiotic series that inhibits bacterial methionyl‑tRNA synthetase with potential oral administration for treatment of Gram‑positive infections.
Microneedle / microarray patch for antiviral and transdermal delivery
Microarray patch prototypes for transdermal delivery of antiviral agents and other payloads to enable non‑invasive delivery routes and potential stockpiling use cases.
Dendrimer‑based heparin reversal therapeutic (preclinical candidate)
A dendrimer‑based platform candidate intended to neutralize heparin activity with the goal of a wider therapeutic window and improved safety relative to existing reversal agents.
Synthetic HDL (sHDL) formulation candidate for infection complications
An sHDL lead candidate designed to treat infection‑related complications such as sepsis, progressed through preclinical development toward GLP toxicology.
Services
Program management and execution of preclinical studies to generate IND‑enabling datasets, including study design, coordination of bioanalysis, PK/PD, formulation, and exploratory toxicology.
Quantitative chemical and bioanalytical testing using HPLC, LC‑MS/MS, validated sample preparation and stability testing.
Prototype formulation design, solubility screening, stability testing and development of transdermal/microneedle patch prototypes.
ADME and PK study design and execution to inform dosing, bioavailability, and clinical planning.
Rodent dosing suites and AAALAC‑accredited vivarium support for exploratory toxicology, biodistribution, and efficacy endpoints.
Assistance developing competitive government proposals, commercialization plans, and acting as or supporting a principal investigator on applications.
Program management and execution of preclinical studies to generate IND‑enabling datasets, including study design, coordination of bioanalysis, PK/PD, formulation, and exploratory toxicology.
Quantitative chemical and bioanalytical testing using HPLC, LC‑MS/MS, validated sample preparation and stability testing.
Prototype formulation design, solubility screening, stability testing and development of transdermal/microneedle patch prototypes.
ADME and PK study design and execution to inform dosing, bioavailability, and clinical planning.
Rodent dosing suites and AAALAC‑accredited vivarium support for exploratory toxicology, biodistribution, and efficacy endpoints.
Assistance developing competitive government proposals, commercialization plans, and acting as or supporting a principal investigator on applications.
Expertise Areas
- IND‑enabling preclinical development
- Formulation development (oral, injectable, transdermal)
- PK/ADME and bioanalytical studies
- Exploratory toxicology and rodent efficacy models
Key Technologies
- HPLC
- LC‑MS/MS
- Spectrophotometry
- Microneedle / microarray patch platforms
News & Updates
TSRL will participate in BIO 2025 at the Michigan Pavilion, showcasing their advancements in drug development and collaborations.
TSRL was awarded a $3 million NIH grant to develop a first-in-class oral antibiotic, aiming to combat drug-resistant bacterial infections.
TSRL received over $4 million in SBIR funding from NIAID to support antiviral prodrug research and development.
A strategic collaboration to accelerate drug development from target identification to IND-enabling studies, announced at BIO 2025.
TSRL sponsors a biotech community event in Ann Arbor to celebrate and promote life sciences innovation.
Announcement of TSRL's participation in BIO 2025 at the Michigan Pavilion, highlighting their role in drug development.
TSRL will participate in BIO 2025 at the Michigan Pavilion, showcasing their advancements in drug development and collaborations.
TSRL was awarded a $3 million NIH grant to develop a first-in-class oral antibiotic, aiming to combat drug-resistant bacterial infections.
TSRL received over $4 million in SBIR funding from NIAID to support antiviral prodrug research and development.
A strategic collaboration to accelerate drug development from target identification to IND-enabling studies, announced at BIO 2025.
TSRL sponsors a biotech community event in Ann Arbor to celebrate and promote life sciences innovation.
Announcement of TSRL's participation in BIO 2025 at the Michigan Pavilion, highlighting their role in drug development.